Medtronic (MDT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT)

MDT 90.06

-0.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jack Hartmann who wrote (561)	2/11/2002 2:53:24 PM
From: Jack Hartmann	Read Replies (1) of 687

Medtronic to benefit from Remodulin OK By Tomi Kilgore Analyst Kevin Kotler at ABN-Amro said final approval of United Therapeutics's (UTHR: news, chart, profile) Remodulin drug could provide incremental upside to Medtronic's (MDT: news, chart, profile) fiscal 2003 estimates. Earlier United Thera. said it had received an approvable letter from the U.S. Food and Drug Administration for Remodulin Injection, a treatment of pulmonary arterial hyperstension (see 10:00 item). Kotler noted that the drug would be delivered by Medtronic's external pump and related disposables. He reiterated his "add" rating on the stock and his $58 price target. The stock is easing 8 cents to $47.35. United Thera is now up $1.71, or 18 percent, at $11.15. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next